关键词: 生物制药, 糖基转移酶, N-糖基化, O-糖基化, 重组糖蛋白

Abstract: Mammalian and non-mammalian protein expression systems have been used in the production of recombinant glycoprotein drugs. Glycosylation is very important for the research and development of biopharmaceuticals, which has an important impact on its efficacy, half-life and antigenicity. The aim of glycosylation engineering is to produce N- and O-linked glycosylated protein drugs with clear components and uniform structure. Recent studies on N-glycosylation have shown that homogeneous recombinant N-glycans can be expressed in mammalian and non-mammalian expression systems. Compared with N-glycosylation, O-glycosylation is still in its infancy. The first glycosylation engineering monoclonal antibody has been approved for marketing in the United States and Japan. This paper reviewed the research progress of glycosylation engineering of recombinant protein expression system, including the progress on N-glycosylation and O-glycosylation, which was expected to provide reference for glycosylation engineering of protein drug research.

Key words: biopharmaceuticals, glycosyltransferases, N-glycosylation, O-glycosylation, recombinant glycoprotein